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ABSTRACT
Introduction. Tumours stimulate the remodelling of their microenvironment for their own survival. To protect 
their own growth and induce angiogenesis, tumours change the structure of the extracellular matrix and 
alter the function of existing as well as chemo-attracting immune system cells. MT is an anti-apoptotic and 
pro-proliferative protein that is also responsible for modulating the response of immune system cells. The 
expression of this protein by the fibroblasts of the tumour microenvironment is probably related to the 
remodelled phenotype of these cells by tumour influence on cancer-associated fibroblasts. Vimentin is 
a protein that appears to be the marker for the mesenchymal transition of cells from the epithelial phe-
notype. These cells seem to acquire the mesenchymal phenotype so that they can migrate and facilitate 
the development of metastases. Interestingly, the expression of vimentin has also been observed in the 
tumour microenvironment and may serve as a marker of a remodelled stroma in the process of facilitating 
tumour spread.
Materials and methods. We recruited 25 patients with tonsillar DLBCL (diffuse large B-cell lymphoma) and 
tonsillar DLBCL with cervical lymph node involvement (i.e. stages I and II of the disease) and analysed 
tissue samples from the lymphoma and tumour microenvironment of each. We also analysed the immu-
noreactivity levels of the following antigens in the palatine tonsil lymphoma and its stroma: MT, vimentin, 
and CD56- and CD57-positive cells.
Results. A statistically significantly higher MT and vimentin immunoreactivity was observed in the lympho-
ma as compared to the stroma tissue samples. However, both MT-positive fibroblasts and MT-positive 
macrophages were observed in the stroma. Additionally, statistically significantly lower numbers of CD56- 
and CD57-positive cells were identified in the lymphoma and the stroma samples than in the reference 
group samples.
Conclusions. The high vimentin immunoreactivity in the tumour and its stroma, together with MT-expressing 
fibroblasts and macrophages, as well as a CD56- and CD57-positive cell deficit, would seem to confirm 
microenvironment remodelling and the participation of MT in tumour remodelling.
Key words: MT, tumour microenvironment, vimentin, tumour-associated macrophages, cancer-associated 
fibroblasts, EMT
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Introduction
Malignant lymphoma is a disease originating pri-
marily from the lymph nodes; however, 24–48% of all 
non-Hodgkin lymphomas (NHL) may arise from extra-
nodal sites. Over the past few decades, the incidence 
of such types of lymphomas has increased [1]. It is 
estimated that 10% of patients with NHL present with 
extranodal disease in the head and neck region [2]. 
While more than half of the head and neck lymphomas 
occur in the Waldeyer’s ring [2, 3], about 40-50% arise 
in the palatine tonsils [4, 5]. The majority of NHL arising 
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from the tonsils are diffuse, large B-cell lymphomas 
(DLBCL) [6, 7].
Metallothioneins are low-molecular weight proteins 
with a high affinity for divalent metals such as zinc and 
copper, as well as toxic metal ions such as cadmium 
and mercury [8, 9]. The ability to bind the metal ions 
is linked to the biological role of these proteins, which 
includes protection against metal toxicity, the reser-
voir of zinc and copper to metalloenzymes during the 
apoptosis process, the production of transcription 
factors, and protection against oxidative stress [8]. 
MTs may also play an important role in the proliferation 
and differentiation of cells [10]. Moreover, it has been 
established that MT expression in the cytoplasm helps 
to protect against cytotoxicity, while its expression in 
the nucleus protects against genotoxicity [8, 10, 11]. 
Genotoxicity concerns the acquisition of cells of the 
malignant phenotype, as a result of mutations critical 
to the carcinogenesis. Cytotoxicity is important in the 
interaction of cancer cells with immune system cells. 
MT expression has been observed in various types of ma-
lignant neoplasms and in cancer microenvironments as 
well as in healthy tissues adjacent to cancer nests [10–12]. 
As has been demonstrated in various studies, MT 
expression in healthy epithelia is localised in the basal 
part of the epithelium, which comprises intensively 
dividing cells responsible for its renewal, while in the 
more superficial layers of the epithelium, which are 
composed of well-differentiated cells, MT expression 
has not been found [13–18]. MT expression has also 
been observed in tumour-adjacent tissue, epithelium, 
and even in tumours without MT expression [13–20].
The tumour microenvironment is the tissue that sup-
ports the tumour’s growth [21]. In our previous studies, 
we demonstrated and analysed the involvement of the 
tumour microenvironment in the development of various 
types of malignant epithelial neoplasms. The micro-
environment was associated with its own remodelling 
and the acquisition of a suppressive tumour microen-
vironment [22–25]. Additionally, we demonstrated the 
presence of tumour microenvironment remodelling with 
RCAS1 expression and RCAS1-positive macrophages in 
the tumour microenvironment of palatine tonsil DLBCL. 
RCAS1 also seemed to be involved in creating tu-
mour-induced inflammation within the tumour and its 
microenvironment [26]. 
Vimentin is a 57 kDa, cytoskeletal protein involved 
in embryonic development. In adults, vimentin expres-
sion is reduced and is mainly observed in connective 
tissue mesenchymal cells in the CNS and in muscles 
[27–34]. Vimentin is expressed in a wide variety of cells, 
including trophoblastic giant cells, fibroblasts, macro-
phages, neutrophils, and leukocytes [11, 28]. The most 
important role of vimentin is related to its involvement in 
the epithelial–mesenchymal transition (EMT) process, 
typified by its expression in epithelial cells, which nor-
mally express only keratin. Physiologically, this process 
is observed during embryonic development, wound 
healing, and chronic inflammation; in pathology me-
tastasising cells demonstrate processes similar to EMT. 
This is significant because EMT has been associated 
with tumour progression [35–37]. Moreover, vimentin 
and MT-1 promoters have recently been shown to be 
epigenetically suppressed by PU.1, a transcription 
factor for haematopoiesis that plays important roles in 
haematological malignancies [38].
In the present study, we aimed to determine the 
immunoreactivity of MT and vimentin in the tumour 
and its microenvironment in palatine tonsils from which 
DLBCLs have originated. 
Materials and methods
For our study, we recruited patients with the most 
common forms of non-Hodgkin lymphoma occurring 
in adults, namely, tonsillar DLBCL (diffuse large B-cell 
lymphoma) and tonsillar DLBCL with cervical lymph 
node involvement (i.e. stages I and II of the disease). We 
selected 25 patients and analysed tissue samples from 
the lymphoma and tumour microenvironment of each. 
The tumour microenvironment or stroma was defined as 
the surrounding tissue with an area of 1 cm2 macroscop-
ically and histologically free of malignant infiltration, and 
with the distance from the tumour front not exceeding 
1 cm. The patient’s consent was obtained in each case. 
Additionally, approval for the research program was 
granted by the Ethical Committee of the Jagiellonian 
University in Krakow (KBET/90/B/2005). All the tissue 
samples were histopathologically verified. Following the 
fixation of the surgically removed material in formalin, 
pathological analysis with classical haematoxylin and 
eosin staining techniques was performed in the Pathol-
ogy Department of the Jagiellonian University by two 
experienced pathologists (R.T. and A.L.) working inde-
pendently. The tissue was first fixated in a solution of 
10% formalin, then rinsed, dehydrated, and transferred 
through a progressively increasing concentration of 
ethanol (from 50% to absolute alcohol), and a series of 
xylenes (I–III) to molten paraffin wax. Finally, the tissue 
blocks were sectioned and the resulting sections placed 
onto glass slides. The process was mainly automated; 
however, both the paraffin embedding and the cutting 
of the tissue samples into 3- to 4-μm-thick sections were 
done manually (Tab. 1).
Reference group
As a reference group, we chose to collect palatine 
tonsils that had been removed from patients suffering 
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Table 1. The characteristics of the patient group
Lymphoma malignum non-Hodgkin B cellular
Patients
   M
   W
25
15
10
Age (range) average
   M
   W
16–84 (55.6)
43–81 (63.8)
16–84 (59.4)
Table 2. The characteristics of the reference group
Palatine tonsils
Number of patients
   M
   W
20
12
8
Age (range) average
   M
   W
14–56 (32.6)
14–56 (34.41)
21–54 (29.87)
from recurrent tonsillitis. In these tissue samples, we 
evaluated both the epithelium lining of the tonsils and 
the lymphoid tissue (Tab. 2).
Immunohistochemical analysis
In the present study, we analysed the immunore-
activity levels of various antigens in the palatine tonsil 
lymphoma and its stroma. We also aimed to evaluate the 
distribution of the antigen immunoreactivity throughout 
the tissue of the tumour, including its stroma. For this 
reason, we chose the immunohistochemical method 
for our study. This is also the only method that shows 
the actual architecture of the interaction between the 
tumour and its stroma. From each tumour, 3–4 tissue 
samples were taken. Each sample was embedded in 
paraffin and formed into a tissue block, which was then 
cut into sections. All the tissue sections were further 
histopathologically verified and immunohistochemistry 
was performed. Two observers, working independently 
and having no knowledge of the clinicopathological 
data, reviewed the immunohistochemical expression 
of MT and vimentin as well as of CD68, CD56, and 
CD57 antigens. Immunohistochemical analysis was per-
formed in the Pathology Department of the Jagiellonian 
University. Five-micrometre slides from each case were 
stained to visualise the expression of MT-, vimentin-, and 
CD68-, CD56-, and CD57-positive cells. In all cases, the 
immunohistochemistry was performed applying the En-
vision method using a Dako Autostainer. The samples 
were stained automatically with immunohistochemical 
staining based on the antigen-antibody reaction. Micro- 
scopy was performed with an Axio Zeiss microscope, 
and the tissue sections were then evaluated under both 
20× and 40× magnification. The following antibodies 
were applied: CD56, CD57 (Novocastra; dilution 1:50), 
vimentin (DAKO, Denmark; dilution 1:50), CD68 (DAKO, 
clone PG-M1; dilution 1:50), and MT (ABCAM; dilution 
1:25) for 10 minutes at room temperature. Visualisation 
of the reaction products was then performed using AEC 
(3-amino-9-ethyl-carbazole) as a chromogen (AEC Sub-
strate Chromogen ready-to-use, DAKO, Denmark) for 
10 minutes at room temperature. Sections were coun-
terstained with haematoxylin and mounted in glycergel. 
As a positive control, a tonsil specimen was taken for 
MT immunostaining. All stainings were performed with 
the same procedure but with the omission of the primary 
antibody as a negative control. Expression for MT and 
vimentin was evaluated in entire sections, both in the 
area of the tumour and in the stroma, as follows: 0 — no 
reactivity; +1 — weak, when any (also granular in para-
nuclear region) cytoplasmic staining pattern observed 
(in up to 10% of positive cells); +2 — marked cytoplas-
mic (sometimes together with membranous staining in 
11-30% of the cells); and +3 — high expression (more 
than 30% of positive cells). Variable scales were used 
to evaluate an amount of the cells semi-quantitatively, 
depending on their general number in the specimen. 
CD56+, CD57+, and CD68+ cells were thus estimated 
as follows: 0 — lack of positive cells; +1 — single posi-
tive cells in the specimen; +2 — 1–5 positive cells/HPF; 
and +3 — more than five positive cells/HPF.
Statistical analysis
The distribution of variables in the study groups of 
women, checked with the use of the Shapiro-Wilk test, 
showed that each of the women was different from 
normal. The statistical significance between the groups 
was determined by the Kruskal-Wallis test, one-way 
analysis of variance by ranks. The Mann-Whitney U 
test was then used as applicable. All statistical analys-
es were carried out with the Statistica 8.0 software 
program. A p value < 0.05 was considered indicative 
of statistical significance.
Results
The immunoreactivity of the various antigens in 
the DLBCL and stromal tissue samples are discussed 
below.
MT immunoreactivity in the lymphoma samples 
and the samples from the reference group 
MT immunoreactivity was observed in 70% of the 
lymphoma tissue samples and in 45% of the stroma tis-
sue samples and represented the nuclear-cytoplasmic 
type of expression. In the stroma samples, MT immuno-
reactivity was observed in stromal fibroblasts (Fig. 1). 
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Figure 1. MT immunoreactivity in the lymphoma of palatine tonsils (arrows) and single fibroblasts in the stroma with MT 
immunoreactivity (stars). A — magnification 20×, B —magnification 40×
Figure 2. MT immunoreactivity in lymphoma cells and 
macrophages, magnification 40×
In the lymphoma tissue samples, MT was observed 
in both lymphoma cells and in tumour-infiltrating macro-
phages (Fig. 2). 
In the reference group, MT immunoreactivity was 
observed in both the lymphatic tissue and the epi-
thelium lining the tonsils. It was present in 85% of the 
lymphatic tissue samples and was represented by 
dispersed spindle-shaped cell-fibroblasts. It was also 
present in 90% of the epithelium tissue samples where 
the immunoreactivity was present in the lower 1/3 of 
the epithelium lining the tonsils and represented the 
membrane-cytoplasmic type of expression (Fig. 3). The 
most prominent MT immunoreactivity was observed in 
the epithelium of tonsillar crypts.
Vimentin immunoreactivity in the lymphoma 
samples and the samples from the reference group
Vimentin immunoreactivity was present in all the lym-
phoma tissue samples and in 80% of the stroma tissue 
Figure 3. MT immunoreactivity in the basal layer of 
epithelium of palatine tonsils crypts
samples and represented a membranous-cytoplasmic 
pattern of expression (Fig. 4).
Strong vimentin immunoreactivity was observed 
in the tissue of the palatine tonsils from patients with 
chronic tonsillitis and in all the samples of lymphatic 
tissue; vimentin immunoreactivity was not observed in 
the epithelium lining the tonsils. 
CD56 immunoreactivity in the lymphoma samples 
and the samples from the reference group
CD56-antigen immunoreactivity was detected in 
10% of the lymphoma tissue samples and in 20% of 
the stromal tissue samples and represented a mem-
branous-cytoplasmic type of expression (Fig. 5). 
CD56-antigen immunoreactivity was observed in 30% 
of the lymphatic tissue samples of the palatine tonsils 
from patients with chronic tonsillitis and represented 
the membranous-cytoplasmic type of expression; it was 
not observed in the epithelium lining the tonsils (Fig. 5).
A B
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A B
Figure 4. Vimentin immunoreactivity in the lymphoma of palatine tonsils and its stroma. A — strong immunoreactivity 
in the stroma, the lymphoma tissue is surrounded by stroma with strong vimentin immunoreactivity (magnification 20×) 
— stars, with a weak immunoreactivity in the tumour tissue-arrows; B — strong immunoreactivity in the stroma — arrows 
and strong immunoreactivity in the peripheral part of tumour nests (magnification 20×). Strong vimentin immunoreactivity 
was observed in the tissue of palatine tonsils under chronic tonsillitis, in all the tissue samples of lymphatic tissue, while 
vimentin immunoreactivity was not observed in the epithelium lining the tonsils
A B
Figure 5. Weak CD56 immunoreactivity in the lymphoid tissue of palatine tonsils of chronic tonsillitis (A) and in lymphoma 
tissue samples (B)
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Figure 6. CD57 antigen immunoreactivity in the tissue of palatine tonsils (A) and in the lymphoma (B)
A B
Table 3. The comparison of analysed antigen immunoreactivity in the tissue of the lymphoma and its stroma
Antigen Lymphoma
Median (Q3–Q1)
Stroma
Median (Q3–Q1)
p value
CD56 0 (0) 0 (1) NS
CD57 1 (0) 1 (0) NS
MT 1 (1) 0 (1) 0.03
Vimentin 2 (1) 1 (1) 0.005
CD57 antigen
CD57-antigen immunoreactivity was detected in 
95% of the lymphoma tissue samples and 85% of the 
stroma samples and represented the membranous- 
-cytoplasmic type of expression (Fig. 6). CD57-antigen 
immunoreactivity was observed in all the samples of 
lymphatic tissue of the palatine tonsils under chronic 
inflammation and represented the membranous- 
-cytoplasmic type of expression. It was not observed in 
the epithelium lining the tonsils (Fig. 6).
The comparison of analysed antigen immunoreac-
tivity in the tissue of the lymphoma and its stroma is 
presented in Table 3. 
A statistically significantly higher level of vimentin 
immunoreactivity was observed in the lymphoma 
tissue samples than in the stroma samples. Similarly, 
statistically significantly higher MT immunoreactivity 
was shown in the lymphoma than in the stroma tissue 
samples. No statistically significant differences were 
observed in CD56- and CD57-antigen immunoreactivity.
Table 4 shows the comparison of analysed antigen 
immunoreactivity in lymphatic tissue and the epithelium 
of the palatine tonsils of patients with chronic tonsillitis. 
A statistically significantly higher MT immunoreac-
tivity was observed in the epithelium lining the tonsils 
in comparison to the lymphatic tissue of the palatine 
tonsils from patients with chronic tonsillitis. Additionally, 
statistically significantly higher vimentin immunoreac-
tivity was detected in the lymphatic tissue of palatine 
tonsils in comparison to the epithelium. 
Table 5 shows the comparison of analysed antigen 
immunoreactivity in the lymphoma tissue samples 
and the lymphatic tissue samples from patients with 
chronic tonsillitis.
Statistically significantly higher MT immunoreactivity 
was observed in the lymphoma tissue samples than in 
the samples from the reference group (lymphatic tissue 
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Table 4. The comparison of the analysed antigen immunoreactivity between the lymphatic tissue and epithelium lining 
the palatine tonsils from patients with chronic tonsillitis
Antigen Lymphatic tissue of the palatine 
tonsils
Median (Q3–Q1)
Epithelium of the tonsils
Median (Q3–Q1)
p value
CD56 0 (1) 0 (0) 0.02
CD57 3 (1) 0 (0) p < 0.0001
MT 1 (1) 2 (1) 0.03
Vimentin 3 (0) 0 (0) p < 0.0001
Table 5. The comparison of analysed antigen immunoreactivity in the lymphoma tissue samples and in the lymphatic 
tissue of patients with chronic tonsillitis
Antigen Lymphoma
Median (O3–Q1)
Lymphatic tissue of palatine tonsils 
under chronic tonsillitis
Median (Q3–Q1)
p value
CD56 0 (0) 0 (1) NS
CD57 1 (0) 3 (1) p < 0.001
MT 2 (1) 1 (1) 0.03
Vimentin 2 (1) 3 (0) p < 0.001
Table 6. The comparison of the analysed antigen immunoreactivity in the stroma and in the epithelium lining the 
palatine tonsils from patients with chronic tonsillitis.
Antigen Stroma
Median (O3–Q1)
Epithelium lining the palatine tonsils 
under chronic tonsillitis
Median (Q3–Q1)
p value
CD56 0 (1) 0 (0) 0.005
CD57 1 (0) 0 (0) p < 0.001
MT 0 (1) 2 (1) p < 0.001
Vimentin 1 (1) 0 (0) p < 0.001
of palatine tonsils from patients with chronic tonsillitis). 
Additionally, statistically significantly higher vimentin 
immunoreactivity was observed in the lymphoma tissue 
samples than in the reference group samples.
Table 6 shows the comparison of analysed antigen 
immunoreactivity in the stroma and the epithelium lining 
the palatine tonsils of patients with chronic tonsillitis. 
Statistically significantly higher immunoreactivity of 
CD56, CD57, and vimentin antigens was observed in 
the stroma of the tumour than in the reference group 
samples. Additionally, statistically significantly higher 
MT immunoreactivity was detected in the reference 
group samples than in the tumour stroma samples. 
Discussion
In the present analysis, MT immunoreactivity was 
demonstrated in the lymphoma cells and was statistical-
ly significantly higher in the tumour tissue samples than 
in the stroma samples and in the tumour tissue samples 
compared to the reference samples. Poulsen et al. 
found MT expression on DLBCL lymphoma cells. They 
also identified a correlation between MT expression 
and prognosis. Specifically, MT labelling of more than 
20% lymphoma cells was associated with a significantly 
poorer five-year survival rate, independent of the age, 
stage, or International Prognostic Index. It was thus sug-
gested that both increased MT mRNA and MT protein 
expression by more than 20% of lymphoma cells are 
independent risk factors for DLBCL [39]. MT is a protein 
that both protects cells against apoptosis and induces 
cell proliferation. MT expression by malignant cells may 
thus have two important consequences: inducing the 
proliferation of malignant cells and developing resis-
tance to the apoptosis stimulated by immune system 
cells. Both of these phenomena enable tumour growth 
and the development of the disease [14]. 
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In the present study, MT immunoreactivity was also 
identified in the tumour stroma samples and was signifi-
cantly lower than in the lymphoma samples. This sole 
MT immunoreactivity presence in the stroma samples 
is intriguing. In the present study, MT immunoreactivity 
was also found to be expressed by the stromal fibro-
blasts. This correlates with the pattern of MT expression 
in other histological tumour types, such as adenocarci-
nomas and squamous cell carcinomas [22–25]. Stroma 
is tissue that undergoes intensive remodelling during 
tumour development, which is also induced by factors 
secreted from its own tumour cells [40]. This remod-
elling is realised according to the tumour scenario 
stimulating its growth. Fibroblasts differentiate into 
myofibroblasts, the basic stromal cells in remodelled 
stroma, which respond to tumour needs (carcinoma- 
-associated fibroblasts or CAFs) [8, 13–14, 22, 23]. 
Moreover, in the present study, MT immunoreactivity 
was also observed on macrophages in the lymphoma 
tissue samples. This observation is in agreement with 
that of Poulsen et al. who showed MT to be present 
in macrophages and that the number of MT-positive 
macrophages did not correlate with the patient’s sur-
vival [39]. Macrophages also play an important role in 
remodelling the tumour microenvironment [40]. Thus, 
MT may be a marker of stroma remodelling and the 
development of tumour-associated fibroblasts and 
macrophages. Numerous authors have also described 
the expression of MT by healthy cells. MT was present 
in the basal layer of the epithelium, which is responsible 
for renewal [14]. In a previous study, we presented MT 
expression in the stroma of both breast and head and 
neck carcinomas [13, 14, 19, 20]. We concluded that 
an aggressive inflammatory infiltrate in the tumour may 
induce MT expression as a development of the resis-
tance to the apoptosis stimulated by immune system 
cells [13, 14, 19, 20]. 
In the present study, vimentin immunoreactivity was 
found in all the lymphoma tissue samples and in 80% of 
the stroma tissue samples. It was significantly higher in 
the lymphoma samples than in the stroma samples, and 
higher again in the lymphoma samples than in the ref-
erence samples. Additionally, it was significantly higher 
in the stroma than in the reference samples. Vimentin 
is one of the markers of mesenchymal phenotype of 
cell acquisition linked with the epithelial–mesenchymal 
transition. This process is typified by the change in ex-
pression of epithelial markers to mesenchymal markers 
such as vimentin and N-cadherin [35]. This process is 
also observed in physiology, for example during wound 
healing, but in pathology the mesenchymal phenotype 
is typical of metastasising cells [41, 42]. MT may there-
fore be together with vimentin the marker of stromal 
remodelling in relation to the epithelial–mesenchymal 
transition (EMT) phenomenon. 
In the present study, the infiltration of CD56- and 
CD57-positive cells into the stroma and lymphoma re-
mained at comparable levels. This correlated with our 
observation of the CD56- and CD57-positive cell infiltra-
tion into adenocarcinoma and its stroma [22]. However, 
a significantly lower infiltration of CD57-positive cells 
was observed in the lymphoma than in the reference 
samples. Thus, the lower level of anticancer response 
represented by CD56- and CD57-positive lymphocytes 
in the lymphoma and its stroma indicates a deficit of this 
response in the analysed lymphoma tissue.
In summary, the high vimentin immunoreactivity in 
the tumour and its stroma, together with the presence 
of MT-expressing fibroblasts and macrophages, would 
seem to confirm microenvironment remodelling as well as 
the participation of MT in the tumour remodelling process. 
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